市場調査レポート

HIVワクチン市場の機会と臨床パイプライン分析

HIV Vaccine Market Opportunity & Clinical Pipeline Analysis

発行 KuicK Research 商品コード 302593
出版日 ページ情報 英文 330 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
HIVワクチン市場の機会と臨床パイプライン分析 HIV Vaccine Market Opportunity & Clinical Pipeline Analysis
出版日: 2014年03月01日 ページ情報: 英文 330 Pages
概要

30年前にHIVがAIDSの原因と特定されて以来、HIVウイルスは世界中の国々が直面する公衆衛生の最大の課題のひとつとなりました。UNAIDSによると、AIDSによる死亡は2012年に150万人近くとなりました。また新たに230万人がHIVに感染し、3,530万人が現在HIV保持者とされています。

当レポートでは、HIVワクチンおよび機序のイントロダクション、世界のHIV発症率動向、研究開発、法規制動向、治験動向などとともに、参入する企業の競合環境をまとめ、概略下記の構成で取り上げております。

第1章 HIVワクチンおよび機序のイントロダクション

  • イントロダクション
  • HIVワクチンの機序

第2章 HIVワクチン:予防と治療

  • 予防
  • 治療と抗レトロウイルス治療へのアクセス

第3章 なぜHIVワクチンが必要なのか

第4章 世界のHIVウイルス市場見通し

  • HIV発症率シナリオ
  • 市場概要
  • 治験分析

第5章 HIVワクチンに関する研究開発費用シナリオ

第6章 市場動向

  • 市場促進因子
  • 解決すべき課題
  • 将来的成長の機会

第7章 HIVワクチン開発に関するFDAの規制枠組み

  • 小児による使用のための予防的HIVワクチンの開発
  • HIV抵抗性データ提出に関するガイダンス
  • 抗レトロウイルス薬剤開発におけるHIV抵抗性検査

第8章 相、国別パイプライン

第9章 相、国別の中断・中止されたHIVワクチン治験プロファイル

第10章 競合環境

  • Antigen Express
  • Bionor Pharma
  • FIT Biotech
  • GeoVax
  • GenVec
  • Glaxo Smithkline
  • Immune Response BioPharma
  • Inovio Pharmaceuticals
  • Novartis
  • Sanofi Pasteur

図表

目次

Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become one of the greatest challenges of public health facing all countries of the world. According to UNAIDS, death due to AIDS was estimated to close to 1.6 million in 2012. There were 2.3 million new HIV infections, and about 35.3 million people currently living with HIV. Given the pace at which the HIV virus is spreading, it is most likely that AIDS would take more lives than any other infectious disease in the future years to come. Inspite of well-expanded programs of prevention and treatment which are currently enabling the stakeholders to address the illness and death associated with HIV and AIDS, the HIV vaccines is considered to be the best solution to end this disease successfully.

HIV/AIDS has become of the leading infectious disease which is taking a huge death toll across the globe, even surpassing TB and malaria. Irrespective of whether the country is developed or developing, the disease is increasingly becoming prevalent, though with serious impact in the developing countries. It has been observed that almost nine out of every ten HIV infections are being diagnosed in the developing countries, and two-thirds are in Sub-Saharan Africa. India currently has close to 4 million infected people, which is the largest number of infected persons of any country in the world. Despite of the combating efforts, the Asian and other developing regions are increasingly feeling the heat as HIV continues to spread at a significant rate.

In recent years there have been significant breakthroughs achieved in terms of prevention and treatment of HIV/AIDS. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and an efficient vaccine, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future.

It is expected that in the next 5-8 years, the pharmaceutical companies would focus more on the development of a successful efficient vaccine to control the spread of this disease. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. There needs to be complete scrutiny of every single technological area of HIV prevention R&D so as to reflect the best methods of channelizing the funds which are limited in nature. The funds need to be specifically directed towards only those products and approaches which have a high probability of succeeding, instead of those which are less promising.

"HIV Vaccine Market Opportunity & Clinical Pipeline Analysis" Report Highlights:

  • Introduction to HIV Vaccine & Mechanism
  • Global HIV Incidence Scenario
  • R&D Funding Scenario for HIV Vaccine
  • FDA Regulatory Framework
  • HIV Vaccine Clinical Trial by Phase & Country
  • HIV Vaccines in Development Phase: More Than 100
  • Most HIV Vaccines in Preclinical Phase: More Than 50
  • Discontinued & Suspended HIV Vaccines Profiles

Table of Contents

1. Introduction to HIV Vaccine & Mechanism

  • 1.1. Introduction
  • 1.2. The Mechanics of HIV Vaccines

2. HIV Vaccine: Prevention & Cure

  • 2.1. Prevention
  • 2.2. Cure & Access to Antiretroviral Therapy

3. Why Need For HIV Vaccines?

4. Global HIV Vaccine Market Outlook

  • 4.1. HIV Incidence Scenario
  • 4.2. Market Overview
  • 4.3. Clinical Trial Analysis

5. Research & Development Funding Scenario for HIV Vaccine

6. HIV Vaccine Market Dynamics

  • 6.1. Favorable Market Drivers
  • 6.2. Challenges to be Resolved
  • 6.3. Future Growth Opportunity

7. FDA Regulatory Framework for Development of HIV Vaccine

  • 7.1. Development of Preventive HIV Vaccines for Use in Paediatric Populations
  • 7.2. Guidance for Submitting HIV Resistance Data
  • 7.3. HIV Resistance Testing in Antiretroviral Drug Development

8. HIV Vaccine Clinical Trial by Phase & Country

  • 8.1. Research
  • 8.2. Preclinical
  • 8.3. Clinical
  • 8.4. Phase I
  • 8.5. Phase I/II
  • 8.6. Phase II
  • 8.7. Phase III

9. Discontinued & Suspended HIV Vaccine Clinical Trial by Phase & Country

  • 9.1. No Development Reported
  • 9.2. Discontinued
  • 9.3. Suspended

10. Competitive Landscape

  • 10.1. Antigen Express
  • 10.2. Bionor Pharma
  • 10.3. FIT Biotech
  • 10.4. GeoVax
  • 10.5. GenVec
  • 10.6. Glaxo Smithkline
  • 10.7. Immune Response BioPharma
  • 10.8. Inovio Pharmaceuticals
  • 10.9. Novartis
  • 10.10. Sanofi Pasteur

List of Figures

  • Figure 1-1: Vaccine Research Process
  • Figure 4-1: People Living With HIV Infection (Million), 2009-2014
  • Figure 4-2: New Incidence of HIV Infection (Million), 2009-2012
  • Figure 4-3: People Living With HIV Infection by Region (%), 2012
  • Figure 4-4: People Accessing Treatment for HIV Infection (Million), 2009-2012
  • Figure 4-5: Global HIV/AIDS Therapeutics Market (US$ Billion), 2012-2018
  • Figure 4-6: HIV Vaccines in Clinical Trial by Phase (%), 2014
  • Figure 4-7: Number of HIV Vaccines in Clinical Trial by Phase, 2014
  • Figure 4-8: Suspended & Discontinued HIV Vaccines in Clinical Trial (%), 2014
  • Figure 4-9: Number of Suspended & Discontinued HIV Vaccines in Clinical Trial, 2014
  • Figure 4-10: Discontinued HIV Vaccines in Clinical Trial by Phase (%), 2014
  • Figure 4-11: Number of Discontinued HIV Vaccines in Clinical Trial by Phase, 2014
  • Figure 4-12: HIV Vaccines in Clinical Trial by Phase Where No Development Reported (%), 2014
  • Figure 4-13: Number of HIV Vaccines in Clinical Trial by Phase Where No Development Reported, 2014
  • Figure 5-1: Global HIV Vaccines R&D Funding (US$ Million), 2005-2012
  • Figure 5-2: Global HIV Vaccines R&D Funding Breakup (%), 2012
  • Figure 5-3: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%),2012

List of Tables

  • Table 5-1: HIV Vaccines Funding by Sector (US$ Million), 2006-2012
  • Table 6-1: HIV Vaccine Impact Analysis on Incidence & Deaths
Back to Top